Follow-up | Bern (Switzerland) | Gdansk (Poland) | Lutsk (Ukraine) | p Value for all | Bern vs Gdansk | Bern vs Lutsk | Gdansk vs Lutsk |
Antiplatelet at follow-up | 98.3% (461) | 83.9% (205) | 78.2% (101) | <0.001 | <0.001 | <0.001 | 0.223 |
Statin at follow-up | 90.9% (461) | 78.5% (205) | 31.7% (101) | <0.001 | <0.001 | <0.001 | <0.001 |
ACEIs or ARB at follow-up | 73.3% (461) | 81% (205) | 34.7% (101) | <0.001 | 0.034 | <0.001 | <0.001 |
β-Blocker at follow-up | 74.4% (461) | 81.5% (205) | 52.5% (101) | <0.001 | 0.047 | <0.001 | <0.001 |
Participation in cardiac rehabilitation | 69.4% (343) | 51.4% (204) | 26% (92) | <0.001 | <0.001 | <0.001 | <0.001 |
3.5 year mortality | 4.6% (547) | 8.5% (375) | 14.6% (164) | <0.001 | 0.014 | <0.001 | 0.033 |
Comparison between the three study centres in regard to follow-up medication, rehabilitation attendance and mortality.
ACEIs, ACE inhibitors; ARB, angiotensin receptor blocker.